The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Clinical Trials Arena on MSN
Gilead’s HIV single-pill combo meets primary endpoints in pivotal trial
Gilead has become a significant name in the HIV landscape after its twice-yearly PrEP treatment Yeztugo touted 99.9% efficacy ...
Researchers say they have found a second patient whose body seemingly had rid itself of the human immunodeficiency virus (HIV) that causes AIDS — supporting hope that it may be possible someday to ...
Researchers say they have found a second patient whose body seemingly had rid itself of the human immunodeficiency virus (HIV) that causes AIDS — supporting hope that it may be possible someday to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback